This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
|Podcasts|July 14, 2021
The Race to Billions How Amplifying Adherent Cultures Can Get You There
Author(s)Corning Life Sciences
In this podcast, we speak with Austin Mogen, Ph.D., Sr. Field Application Scientist and Cat Siler, Ph.D., Field Application Scientist both from Corning Life Sciences about the available platforms for adherent cell culture scale-up. These platforms offer the potential to reduce time and cost while delivering high efficiency for a variety of adherent applications.
Related to this article
FDA approves Sun Pharma’s Ilumya for active psoriatic arthritis, BioMarin licenses a subcutaneous Fabry enzyme replacement therapy from GC Biopharma and Hanmi, and Lonza expands bioconjugation capacity in Visp to meet rising ADC demand.
In the second part of an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 414 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
The first-in-class molecule, licensed to Dianthus as DNTH212 outside Greater China, is designed to block type 1 interferon production and BAFF/APRIL-driven B-cell activity with a single drug.
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.
Trending on BioPharm International
1
Aclaris’ TSLP/IL-4Rα Bispecific ATI-052 Shows Early Activity in Atopic Dermatitis and Asthma
2
Lilly’s Retatrutide Doubles Ozempic’s Weight Loss in First Phase 3 Head-to-Head Trial
3
Immatics’ PRAME-Targeted TCR Bispecific IMA402 Shows 32% Response Rate in PRAME-High Tumors
4
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
5